Abstract
In searching for better anticonvulsant drug and the importance of semicarbazones and 2,5-disubstituted 1,3,4- oxadiazoles as anticonvulsant pharmacophore, a series of novel substituted semicarbazones were designed, synthesized and evaluated for their anticonvulsant activity. Among all the synthesized compounds, N1-(5-{2-[(2,6- dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxyphenyl)(phenyl) methanone]-semicarbazone 12 emerged out as the most potent compound, showing considerable activity in maximal electroshock seizure (at 100 mg/kg after 0.5 h and at 300 mg/kg after 4.0 h) and subcutaneous pentylenetrtrazole model (at 300 mg/kg after 4.0 h) without any neurotoxicity (up to 300 mg/kg after 4.0 h). The results of the present study validated that the pharmacophore model with four binding sites is essential for anticonvulsant activity.
Keywords: 1,3,4-Oxadiazoles, Semicarbazones, Anticonvulsant activity, Neurotoxicity
Letters in Drug Design & Discovery
Title: Anticonvulsant Activity of A Novel Series of 2,5-Disubstituted 1,3,4-Oxadiazoles: Semicarbazones Based Pharmacophoric Model Studies
Volume: 6 Issue: 6
Author(s): Harish Rajak, Ravichandran Veerasamy, Pradeep Singour, Murli Dhar Kharya and Pradeep Mishra
Affiliation:
Keywords: 1,3,4-Oxadiazoles, Semicarbazones, Anticonvulsant activity, Neurotoxicity
Abstract: In searching for better anticonvulsant drug and the importance of semicarbazones and 2,5-disubstituted 1,3,4- oxadiazoles as anticonvulsant pharmacophore, a series of novel substituted semicarbazones were designed, synthesized and evaluated for their anticonvulsant activity. Among all the synthesized compounds, N1-(5-{2-[(2,6- dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxyphenyl)(phenyl) methanone]-semicarbazone 12 emerged out as the most potent compound, showing considerable activity in maximal electroshock seizure (at 100 mg/kg after 0.5 h and at 300 mg/kg after 4.0 h) and subcutaneous pentylenetrtrazole model (at 300 mg/kg after 4.0 h) without any neurotoxicity (up to 300 mg/kg after 4.0 h). The results of the present study validated that the pharmacophore model with four binding sites is essential for anticonvulsant activity.
Export Options
About this article
Cite this article as:
Rajak Harish, Veerasamy Ravichandran, Singour Pradeep, Kharya Dhar Murli and Mishra Pradeep, Anticonvulsant Activity of A Novel Series of 2,5-Disubstituted 1,3,4-Oxadiazoles: Semicarbazones Based Pharmacophoric Model Studies, Letters in Drug Design & Discovery 2009; 6 (6) . https://dx.doi.org/10.2174/157018009789057571
DOI https://dx.doi.org/10.2174/157018009789057571 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology Opening New Scenarios for Human MAO Inhibitors
Central Nervous System Agents in Medicinal Chemistry The Plastic Phenomenon Underlying the Associative Processes in the Addictive Properties of Diazepam and Other Psychoactive Drugs
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Insulin and the Brain
Current Diabetes Reviews Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Emerging Signalling and Protein Interactions Mediated Via Metabotropic Glutamate Receptors
Current Drug Targets - CNS & Neurological Disorders Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Can FreeSurfer Compete with Manual Volumetric Measurements in Alzheimer’s Disease?
Current Alzheimer Research Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Preface
Current Pharmaceutical Design GABAergic Drugs for the Treatment of Migraine
CNS & Neurological Disorders - Drug Targets Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry Prevalence of Cognitive Impairment and Dementia in Malays – Epidemiology of Dementia in Singapore Study
Current Alzheimer Research Elaboration and Validation of HPLC/DAD Method for Quality Control of Products Containing Cannabidiol
Current Pharmaceutical Analysis Adult Neurogenesis in Epileptogenesis: An Update for Preclinical Finding and Potential Clinical Translation
Current Neuropharmacology TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Infectious Disorders - Drug Targets The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design